NNVC - NanoViricides, Inc.
| Previous Close | 0.1750 |
| Open | 0.1855 |
| Bid | 0.1845 x 3000 |
| Ask | 0.1997 x 1000 |
| Day's Range | 0.1845 - 0.1970 |
| 52 Week Range | 0.1600 - 0.6800 |
| Volume | 271,249 |
| Avg. Volume | 108,325 |
| Market Cap | 14.188M |
| Beta (3Y Monthly) | 1.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1200 |
| Earnings Date | Oct 10, 2019 - Oct 14, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.60 |
- Simply Wall St.
What Percentage Of NanoViricides, Inc. (NYSEMKT:NNVC) Shares Do Insiders Own?
The big shareholder groups in NanoViricides, Inc. (NYSEMKT:NNVC) have power over the company. Insiders often own a...
- PR Newswire
NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split
SHELTON, Conn., Sept. 12, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), announced today that its Board of Directors has approved a 1-for-20 reverse split of all of the Company's capital stock, including its common stock, which will be effective after the market closes on September 23, 2019. The common stock will begin trading on a split-adjusted basis on September 24, 2019. The reverse split will affect all securities of the Company uniformly.
- PR Newswire
NanoViricides, Inc. Has Filed its Annual Report, Company Advancing Rapidly Towards First IND
SHELTON, Conn., Aug. 26, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), reports that it has filed its annual report (Form 10-K) for the financial year ending June 30, 2019, with the Securities and Exchange Commission (SEC) on Friday, August 23, 2019. The Company reported that, as of June 30, 2019, it had cash and cash equivalent current assets balance of approximately $2.8 Million. The strong P&E assets comprise the Company's fully owned cGMP-capable manufacturing and R&D facility in Shelton, CT.
- PR Newswire
NanoViricides Reports Its First Drug Candidate is on Track with GLP Safety/Toxicology Studies toward Human Clinical Trials
SHELTON, Conn., Aug. 5, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, based on the nanoviricdes® platform, announces that its first drug candidate, NV-HHV-101, is on track with required preclinical GLP Safety and Toxicology studies moving towards human clinical trials. The Company reports that NV-HHV-101 has been found to be safe and well tolerated in the clinical observation portion of the GLP Safety/Toxicology study of NV-HHV-101 as a dermal treatment. The in-life stage of the first part of the GLP studies is complete, allowing assessment of clinical observations.
- Simply Wall St.
Does The NanoViricides, Inc. (NYSEMKT:NNVC) Share Price Fall With The Market?
Anyone researching NanoViricides, Inc. (NYSEMKT:NNVC) might want to consider the historical volatility of the share...
- PR Newswire
NanoViricides, Inc. Appoints Dr. Mark Day to its Board of Directors
SHELTON, Conn., June 10, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, reports that Dr. Mark Day has been duly appointed as an Independent Director to its Board of Directors, effective June 6, 2019. Dr. Day has over 16 years of experience in the pharmaceutical industry with extensive experience in opportunity due diligence and in-licensing at big pharma as well as out-licensing from biotech.
- PR Newswire
NanoViricides has Received Favorable FDA Comments on Its Pre-IND Application for the Lead Drug Candidate
SHELTON, Conn., June 3, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a company with novel platform technology to fulfill unmet medical needs in treating difficult and life-threatening viral diseases, reports that it has received favorable comments from the US FDA on the Company's pre-IND application for its lead drug candidate. The Company reports that the US FDA (the Agency) has generally agreed in its pre-IND response that the plan of drug development presented by the Company to the FDA is generally adequate at this time.
- PR Newswire
NanoViricides Files Quarterly Report for Period Ending March 31, 2019 - HerpeCide™ Drug Candidate Pre-IND Application Submitted, Progressing Towards Clinical Trials
SHELTON, Conn., May 20, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its third quarter of financial year 2019 in a timely manner with the Securities and Exchange Commission. The Company reported that it had approximately $4.63Million (M) of current assets (cash, cash equivalents, and prepaid expenses), and current cash liabilities of approximately $1.08M, as of March 31, 2019, the end of the reporting period. The net cash used in operating activities during the last nine months (last three quarters) was approximately $5.13M, compared to approximately $4.26M in the nine months ending March 31, 2018. The Company's expenditures were in line with budget estimates.
- Simply Wall St.
Some NanoViricides (NYSEMKT:NNVC) Shareholders Have Taken A Painful 92% Share Price Drop
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Spare a thought for those who held NanoViricides, Inc. (NYSEMKT:NNVC) for five whole years - as the share price tanked 92%. And some of t...
- PR Newswire
NanoViricides Submits Pre-IND Briefing Documents to the US FDA
SHELTON, Conn., April 16, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a company with novel platform technology to meet unmet medical needs in treating difficult and life-threatening viral diseases, reports that it has submitted the required pre-IND Briefing Documents for its lead drug candidate NV-HHV-101 to the US FDA, ahead of schedule. The Company is developing NV-HHV-101 as a broad-spectrum drug against a number of herpes viruses. The Company has chosen shingles rash as the first indication for this drug candidate.
- PR Newswire
NanoViricides Provides Update on Pre-IND Meeting with the US FDA, GLP Safety/Toxicology Studies to Begin Soon, Multiple Kg Scale Drug Production Accomplished at Its Own Facility
SHELTON, Conn., April 9, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a company with novel platform technology to treat difficult and life-threatening viral diseases, reports that US FDA has responded to its request for a pre-IND meeting. In addition, the Company reports that it has completed production of the drug product for the ensuing GLP Safety/Toxicology studies of its lead drug candidate in the HerpeCide™ program. The Company reports that it has successfully completed the scale-up of the chemistries and production of kg-scale quantities of the drug substance or API, NV-HHV-101.
- PR Newswire
NanoViricides has Requested a Pre-IND Meeting with the US FDA
SHELTON, Conn., March 26, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a company with novel platform technology to treat difficult and life-threatening viral diseases, announces that it has requested a pre-IND meeting with the US FDA, as it progresses its lead drug candidate towards human clinical trials. The Company recently reported that its first broad-spectrum drug candidate in the HerpeCide™ program, namely, NV-HHV-101, has successfully completed the non-GLP portion of the Safety/Toxicology studies that are required for filing an IND in order to initiate human clinical trials. The Company is now in the process of manufacturing a large batch of the drug as needed for the GLP portion of the Safety/Toxicology studies.
- PR Newswire
NanoViricides Reports Successful Completion of Another Important Safety Study towards an IND
SHELTON, Conn., March 12, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a company with novel platform technology to treat difficult and life-threatening viral diseases, announces that its first drug candidate has successfully completed another important step in its Safety/Toxicology studies moving towards human clinical trials. The broad-spectrum anti-herpes clinical candidate in the HerpeCide™ program, namely NV-HHV-101, was tested in this study, formulated as a subcutaneous injection, to determine potential systemic safety and toxicological effects. While NV-HHV-101 is designed and developed as a dermal topical cream, it is important to determine if any systemically absorbed portion of the drug can have deleterious effects.
- PR Newswire
NanoViricides Reports Excellent Safety Profile of Its First Drug Candidate in Dermal Treatment Study
SHELTON, Conn., Mar. 5, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a company with novel platform technology to treat difficult and life-threatening viral diseases, announces that its first drug candidate has successfully completed the first of the Safety/Toxicology studies moving towards human clinical trials. The Company is developing its broad-spectrum drug candidate in the HerpeCide™ program, namely, "NV-HHV-101," towards human clinical trials. The drug candidate is formulated as a dermal topical cream.The first part of the IND-enabling safety/toxicology studies comprised a non-GLP evaluation of safety and tolerability of the drug candidate in mini-pigs.
- PR Newswire
NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering
SHELTON, Conn., Feb. 27, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), announced today that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 6,944,446 units at a price of $0.36 per unit. Each unit comprises 1 share of common stock and 1 five-year warrant exercisable at $0.61. The shares of common stock and warrants were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-216345), which was declared effective by the United States Securities and Exchange Commission ("SEC") on April 25, 2017.
- PR Newswire
NanoViricides Reaches an Agreement on Terms of License for Shingles Virus Drug Development
SHELTON, Conn., Feb. 26, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), reported today that it has reached an agreement on the terms of the license for the drug development against VZV, the virus that causes chickenpox in children and shingles in adults. NanoViricides previously tested the nanoviricide® drug candidates being developed for HSV-1 against VZV in cell cultures and found them to be highly effective, in early 2017. The Company continued further development of these drug candidates against VZV while it was continuing to develop new collaborations for animal testing of its HSV-1 and HSV-2 drug candidates.
- Associated Press
NanoViricides: Fiscal 2Q Earnings Snapshot
The Shelton, Connecticut-based company said it had a loss of 3 cents per share. The company's shares closed at 39 cents. A year ago, they were trading at $1. _____ This story was generated by Automated ...
- PR Newswire
NanoViricides Files Quarterly Report for Period Ending December 31, 2018 - HerpeCide Drug Candidate Progressing in IND-Enabling Studies Towards Clinical Trials
SHELTON, Conn., Feb. 19, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its second quarter of financial year 2019 in a timely manner with the Securities and Exchange Commission. The Company reported that it had approximately $4.07 Million (M) of current assets (cash, cash equivalents, and prepaid expenses), and current cash liabilities of approximately $1.16M, as of December 31, 2018, the end of the reporting period. The net cash used in operating activities during the last six months (first and second quarters) was approximately $3.12 M, compared to approximately $2.96M in the six months ending December 31, 2017. The Company's expenditures were in line with budget estimates.
- PR Newswire
NanoViricides President Dr. Diwan to Present at the BIO CEO & Investor 2019 Event in New York City Tomorrow Feb 12th at 2:30pm
SHELTON, Conn., Feb. 11, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a company with a novel platform technology to treat difficult and life-threatening viral diseases, announces that its President Dr. Anil Diwan will present the Company at the BIO CEO & Investor Conference being held at the New York Marriott Marquis on Feb 11th and 12th, 2019. BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Dr. Diwan will present the Company's technology platform and its progress in taking the first drug candidate into human clinical trials.
- PR Newswire
NanoViricides Has Initiated IND-Enabling Safety/Toxicology Studies for Its First Drug Candidate Moving towards Human Clinical Trials
SHELTON, Conn., Feb. 4, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a company with novel platform technology to treat difficult and life-threatening viral diseases, announces that its first drug candidate has now entered IND-enabling Safety/Toxicology studies moving towards human clinical trials. The first part of the IND-enabling Safety/Toxicology studies for the shingles drug candidate began towards the end of December, 2018. The Company expects to report on these various studies as soon as the data become available to us and is reviewed by our scientists.
- Zacks Small Cap Research
NNVC: Initiating Coverage
NanoViricides, Inc. (NNVC) is an early stage nano-pharmaceutical company that was first listed in 2005 and became a reporting company the following year. The company is involved in discovering and developing therapeutics for treating viral infections with drug candidates in the preclinical stage. NanoViricides is currently focused on the development of a potential candidate for the treatment of shingles (herpes zoster), which is caused by the reactivation of varicella zoster virus (VZV).
- PR Newswire
NanoViricides, Inc. CEO Dr. Taraporewala To Present At The Biotech Showcase™ Investment Conference In San Francisco on January 7, 2019
SHELTON, Conn., Jan. 2, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE AMER: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, today announced it will be featured as a presenting company at the Biotech ShowcaseTM Investor Conference. The conference is being held on January 7-9, 2019 at the Hilton Union Square Hotel in San Francisco, CA. Irach B. Taraporewala, Ph.D., CEO of NanoViricides, Inc., will provide an overview of the Company's business and recent progress in moving the company drug pipeline forward towards an Investigational New Drug (IND) Application during the presentation.
- Associated Press
NanoViricides: Fiscal 1Q Earnings Snapshot
On a per-share basis, the Shelton, Connecticut-based company said it had a loss of 3 cents. The company's shares closed at 35 cents. A year ago, they were trading at 98 cents. _____ This story was generated ...
- PR Newswire
NanoViricides Files Quarterly Report for Period Ending September 30, 2018
SHELTON, Conn., Nov. 26, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its first quarter of financial year 2019 in a timely manner with the Securities and Exchange Commission. The Company reported that it had approximately $6.28 Million (M) of current assets (cash, cash equivalents, and prepaid expenses), and current cash liabilities of approximately $1.39M, as of September 30, 2018, the end of the reporting period. The net cash used in operating activities during the last three months (first quarter) was approximately $0.96 M, compared to approximately $1.56M in the three months ending September 30, 2017. The Company's expenditures were in line with budget estimates.
